EXHIBITORS


Diagnostic Imaging Systems, Inc. ......................... 15085 2325 E Saint Charles St Rapid City, SD 57703 Phone: (605) 341-2433 Email: scott@vetxray.com www.vetxray.com (See our ad on page 69.)


Diagnostic Imaging Systems, privately owned since 1983, provides quality imaging equipment—DR Flat Panels, Portable X-Ray, CR Systems, Portable and Wireless Ultrasounds, Exam Tables, and more! DIS provides the best value


EQUISUL-SDT CAUTION


Federal law (USA) restricts this drug to use by or on the order of a licensed veterinarian.


DESCRIPTION EQUISUL-SDT is a broad-spectrum antimicrobial from the potentiated sulfonamide class of chemotherapeutic agents. These two drugs block different sequential steps in the biosynthesis of nucleic acids. Sulfadiazine inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid. Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by reversibly inhibiting dihydrofolate reductase. The effect of the dual action is to reduce the minimum inhibitory concentration of each agent (synergism) and to convert a bacteriostatic action to a bactericidal action. Sulfadiazine is the non-proprietary name for 4-amino-N-2-pyrimidinylbenzenesulfonamide. Trimethoprim is the non-proprietary name for 5-[(3,4,5¬trimethoxyphenyl)methyl]-2,4-pyrimidinediamine.


Figure 1. Structure of sulfadiazine ®


(Sulfadiazine/Trimethoprim) Oral Suspension For use in horses only. Approved by FDA under NADA # 141-360


with the best prices and industry-leading service and warranties. Come by the booth to see new Wireless Flat Panels starting under $20k!


Upcoming AAEP CE Opportunity


24th Annual Resort Symposium Sponsored by Zoetis Jan. 23–25, 2023 Kimpton Seafi re Resort in Grand Cayman Learn more at aaep.org/meetings.


to sulfonamides or trimethoprim should avoid exposure to this product. If an allergic reaction occurs (e.g., skin


medical attention. PRECAUTIONS


Prescribing antibacterial drugs in the absence of a proven or strongly suspected bacterial infection is unlikely to provide


development of drug-resistant animal pathogens.


The administration of antimicrobials, including sulfadiazine and trimethoprim, to horses under conditions of stress may be associated with acute diarrhea that can be fatal. If acute diarrhea or persistent changes in fecal consistency are observed, additional doses of EQUISUL-SDT should not be administered and appropriate therapy should be initiated.


The safe use of EQUISUL-SDT has not been evaluated in breeding, pregnant, or lactating horses. Potentiated sulfonamides should only be used in pregnant or lactating


fetus. Use of potentiated sulfonamides during pregnancy has been associated with an increased risk of congenital


humans, sulfonamides pass through the placenta, are excreted in milk, and may cause hyperbilirubinemia-induced neurotoxicity in nursing neonates.


Decreased hematopoetic activity and blood dyscrasias have been associated with the use of elevated doses and/ or prolonged administration of potentiated sulfonamides. EQUISUL-SDT should be discontinued if prolonged clotting times, or decreased platelet, white blood cell or red blood cell counts are observed.


Figure 2. Structure of trimethoprim


Sulfonamides should be used with caution in horses with impaired hepatic function. Although rare, sulfonamide use has been associated with fulminant hepatic necrosis in humans.


Neurologic abnormalities have been reported in several species following administration of potentiated sulfonamides. In horses, potentiated sulfonamides have been associated with gait alterations and behavior changes that resolved after discontinuation of the drug.


Each mL of EQUISUL-SDT contains 400 mg combined active ingredients (333 mg sulfadiazine and 67 mg trimethoprim) in an aqueous suspension.


INDICATION EQUISUL-SDT is indicated for the treatment of lower respiratory tract infections in horses caused by susceptible strains of Streptococcus equi subsp. zooepidemicus.


DOSAGE AND ADMINISTRATION Shake well before use.


Administer EQUISUL-SDT orally at the dosage of 24 mg combined active ingredients per kilogram body weight (10.9 mg/lb) twice daily for 10 days. EQUISUL-SDT can be administered by volume at 2.7 mL per 45.4 kg (2.7 mL/100 lb) body weight.


EQUISUL-SDT in containers of 280 mL and 560 mL with draw-off caps: Remove cap. Peel off white foil backed bottle seal and replace cap. Peel off outer cap seal exposing (hole) opening. Push an oral tip syringe into the cap opening. Invert and draw out appropriate volume of EQUISUL-SDT solution. (Note: Do not remove syringe while the bottle is inverted as possible spillage may result.) Detach syringe and administer orally at the dosage of 24 mg combined active ingredients per kilogram body weight (10.9 mg/lb) twice daily for 10 days. EQUISUL-SDT can be administered by volume at 2.7 mL per 45.4 kg (2.7 mL/100 lb) body weight.


CONTRAINDICATIONS EQUISUL-SDT is contraindicated in horses with a known allergy to sulfadiazine, sulfonamide class antimicrobials, or trimethoprim.


WARNING


Do not use in horses intended for human consumption. HUMAN WARNINGS


Not for use in humans. For use in animals only. Keep this and all drugs out of the reach of children. Consult a physician in the case of accidental human exposure.


Antimicrobial drugs, including sulfonamides, can cause mild to severe allergic reactions in some individuals. Avoid direct contact of the product with the skin, eyes, mouth, and clothing. Persons with a known sensitivity


The safe use of EQUISUL-SDT has not been evaluated in horses less than 1 year of age.


ADVERSE REACTIONS


of various breeds, ranging from 1 to 25 years of age, which had been treated with either EQUISUL-SDT (n = 182) or with a saline control (n = 88) are summarized in Table 1. At least one episode of loose stool of varying severity was observed in 69 of 182 (38%) of the EQUISUL-SDT-treated horses, and 29 of 88 (33%) saline control horses. Of those animals experiencing loose stool, 2 of 182 (1.1%) of the EQUISUL-SDT-treated horses and 0 of 88 (0%) placebo- treated horses were removed from the study due to diarrhea


of diarrhea in this study were self-limiting and resolved without treatment within 5–10 days after discontinuation of EQUISUL-SDT.


Table 1. Number of Horses with Adverse Reactions During the Field Study with EQUISUL-SDT


Adverse Reactions


Loose stool


(including diarrhea) Colic


Diarrhea


Equisul-SDT (n=182)


69 (38%)


3 (1.6%) 2 (1.1%)


Saline control (n=88)


29 (33%)


2 (2.2%) 0 (0%)


To report suspected adverse events, for technical assistance or to obtain a copy of the SDS, contact Aurora Pharmaceutical, Inc. at 1-888-215-1256 or www.aurorapharmaceutical.com. For additional informa- tion about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.


CLINICAL PHARMACOLOGY


Following oral administration, EQUISUL-SDT is rapidly absorbed and widely distributed throughout body tissues. Sulfadiazine levels are usually highest in the kidney, while the tissue concentration in other tissues is only slightly lower than plasma concentrations. Concentrations of trimethoprim are usually higher in the lungs, kidney, and liver than in the blood. Sulfadiazine and trimethoprim are both eliminated


Diamond V ..................20083/20085 2525 60th Ave SW Cedar Rapids, IA 52404 Phone: (319) 366-0745


Email: diamondv@diamondv.com www.diamondv.com


Diamond V’s TruEquine™ postbiotic is a research-proven equine feed and EFFECTIVENESS


tubular secretion. Urine concentrations of both sulfadiazine and trimethoprim are several-fold higher than blood concentrations.1 Sulfadiazine and trimethoprim are 20% and 35% bound to plasma protein, respectively. Administration of sulfadiazine and trimethoprim with food has no apparent effect on the absorption of sulfadiazine but the absorption of trimethoprim is decreased.


following repeat oral administration of 24 mg/kg EQUISUL-SDT to 6 horses reached peak concentration in 0.5 to 12.0 hours. The median plasma elimination half-life was 3 hours, with a range of 2.31 to 4.96 hours. Peak sulfadiazine concentrations were reached within 1.0 to 12.0 hours in the same study. The median plasma elimination half-life for sulfadiazine was approximately 7.80 hours, with a range of 6.78 to 10.39 hours. Only minor accumulation of both drugs was observed following repeat oral administration of EQUISUL-SDT and both drugs reached steady state by day 3. Sulfadiazine and trimethoprim key steady state parameters associated with administration in 6 fed horses over a period of 7 days are found in Table 2.


Table 2. Median (Range) of sulfadiazine and trimethoprim pharmacokinetics parameters following repeat dosing of 24 mg/kg bid EQUISUL-SDT for 7 days to six horses in fed condition


Drug Tmax (hr)


Cmax (µg/mL)


AUC 0–12 (last dose) (hr*µg/mL)


T 1/2 (hr)


Sulfadiazine Trimethoprim 4.75


8.50


(1.00–12.00) 17.63


(10.10–31.15) 159.35


(73.90–282.54) 7.80


(6.78–10.39)


(0.50–12.00) 0.78


(0.60–1.14) 5.47


(3.31–10.91) 3.00


(2.31–4.96)


MICROBIOLOGY EQUISUL-SDT is the combination of the sulfonamide sulfa- diazine and trimethoprim. These two drugs block sequential steps in nucleic acids biosynthesis. Sulfadiazine inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid. Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by reversibly inhibiting dihydrofolate reductase. The two drugs act synergistically, reducing the minimum inhibitory concentration of each, while enhancing the bacteriostatic action of each separately to a bactericidal action when combined.


EQUISUL-SDT administered as a combined sulfadiazine- trimethoprim dose of 24 mg/kg body weight twice daily for 7 days provided concentrations of sulfadiazine and trimethoprim with T>MIC90 (%T) values of 100% and 98% respectively. The minimum inhibitory concentration (MIC) values for EQUISUL-SDT against indicated pathogens isolat- ed from lower respiratory tract infections in horses enrolled


Table 3. All MICs were determined in accordance with the Clinical and Laboratory Standards Institute (CLSI) Approved Standard M31-A3 using a broth microdilution system and 3% lysed horse blood.


Table 3. Trimethoprim/sulfadiazine minimum inhibitory concentration (MIC) valuesa of isolates recovered from horses with lower respiratory infection caused by Streptococcus equi subsp. zooepidemicus treated with EQUISUL-SDT in the U.S. (2010–2011)


Treatment Outcome Number of Isolates


Time of Sample Collection


MIC 50b (µg/mL)


MIC 90b (µg/mL)


MIC Range (µg/mL)


Success 65c


Pre-


Treatment 0.25/4.75


0.25/4.75


0.12/2.4 to 0.5/9.5


Failure 46


Pre-


Treatment 0.25/4.75


0.25/4.75


0.12/2.4 to 0.5/9.5


a The correlation between in vitro susceptibility data and clinical effectiveness is unknown.


c One isolate of S. equi subsp. zooepidemicus was not tested.


b The lowest MIC to encompass 50% and 90% of the most susceptible isolates, respectively.


[footnote]


1 Kahn CM, Line S, eds. The Merck Veterinary Manual. 10th Ed. Merck & Co. 2010.


01/2021 -


ed the effectiveness of EQUISUL-SDT administered at 24 mg/kg body weight, orally, twice daily for 10 days for the treatment of lower respiratory tract infections in horses caused by Streptococcus equi subsp. zooepidemicus. In this study, a total of 182 horses were treated with EQUISUL-SDT, and 88 horses were treated with saline. One hundred seventy-three horses (112 EQUISUL-SDT and 61 saline) were included in the statistical analysis. Therapeutic success was characterized by absence of fever and no worsening


improvement or resolution of clinical signs of lower respiratory tract infection by Day 17. The observed success rates are 58.9% (66/112) and 14.8% (9/61) for the EQUISUL-SDT and saline-treated groups, respectively.


Table 4 summarizes the statistical analysis results on the overall success rate.


Table 4. Overall Clinical Effectiveness Results Equisul-SDT Saline P-value*


Least Square Means 61% 13.1% 0.0123


* P-value and estimated success rates are based on back- transformed mean estimates from the statistical analysis.


ANIMAL SAFETY


In a target animal safety study, EQUISUL-SDT was adminis- tered orally to 32 healthy adult horses at 0 (0X), 24 (1X), 72 (3X), or 120 (5X) mg/kg twice daily for 30 days. Loose stool was the most common abnormal observation. Observations of loose stool (pellets with liquid or unformed/ cowpile stool) occurred more often in horses treated with EQUISUL-SDT with the incidence of loose stool increasing in a dose related manner. All incidents of loose stool were self-limiting and resolved without treatment.


Horses in all EQUISUL-SDT groups demonstrated statistically and those in the 3X and 5X groups demonstrated statistically


Statistically higher mean neutrophil counts and mean serum gamma glutamyl transferase (GGT) activity were seen in the 1X and 5X groups. Individual animal creatinine, GGT, and albumin concentrations remained within the reference range. Individual animal elevations in absolute neutrophil counts ranged up to 7.09 x 103/mcL (reference range: 1.96-5.31 x 103/mcL).


it was noted that the sulfadiazine and trimethoprim plasma concentrations did not increase in proportion to dose. For sulfadiazine, a 3X and 5X dose resulted in an average exposure of 2.0X and 2.6X the concentrations observed following a 1X dose. For trimethoprim, the corresponding values were 2.5X and 3.5X as compared to the 1X dose.


sulfadiazine, resulted in substantial overlap of individual STORAGE CONDITIONS


to 104° F (40° C) are permitted. Protect from freezing. EQUISUL-SDT in containers of 280 mL and 560 mL — discard 60 days after removing bottle seal.


HOW SUPPLIED EQUISUL-SDT is available in the following package sizes: 135 mL 280 mL 560 mL 900 mL


54


AAEP | 68th Annual Convention 2022 San Antonio


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116